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Brown adipose tissue dissipates energy through
heat and functions as a defense against cold and
obesity. PPARg ligands have been shown to induce
the browning of white adipocytes; however, the
underlying mechanisms remain unclear. Here, we
show that PPARg ligands require full agonism to
induce a brown fat gene program preferentially in
subcutaneous white adipose. These effects require
expression of PRDM16, a factor that controls the
development of classical brown fat. Depletion of
PRDM16 blunts the effects of the PPARg agonist ro-
siglitazone on the induced brown fat gene program.
Conversely, PRDM16 and rosiglitazone synergisti-
cally activate the brown fat gene program in vivo.
This synergy is tightly associated with an increased
accumulation of PRDM16 protein, due in large
measure to an increase in the half-life of the protein
in agonist treated cells. Identifying compounds that
stabilize PRDM16 protein may represent a plausible
therapeutic pathway for the treatment of obesity
and diabetes.
INTRODUCTION
White adipose tissue (WAT) functions to store excess energy as
triglycerides, whereas brown adipose tissue (BAT) is specialized
to dissipate chemical energy as heat. The developmental and
transcriptional control of BAT has received much attention over
the last several years, mainly because of its potential role in
the defense against obesity and obesity-associated disorders
(reviewed in [Enerba¨ck, 2010]). Recent findings using 18fluoro-
labeled 2-deoxy-glucose positron emission tomography
(18FDG-PET) scanning have shown clearly that most if not all
normal adult humans have distinct brown fat deposits. The ther-
mogenic activity of this tissue correlates inversely with overall
adiposity, raising the possibility that variation in the amount or
activity of BAT may contribute to the propensity for weight gain
in humans (Cypess et al., 2009; Nedergaard et al., 2007; Saito
et al., 2009; van Marken Lichtenbelt et al., 2009; Virtanen et al.,
2009; Yoneshiro et al., 2011). Recent research has also identified
several dominant transcriptional regulators of brown adipocyteCedevelopment and function, including peroxisome proliferator-
activated receptor gamma coactivator 1a (PGC1a), FoxC2
(Forkhead box C2) and PRDM16 (PRD1-BF-1-RIZ1 homologous
domain containing protein-16) (reviewed in [Kajimura et al.,
2010]) Genetic loss of PGC1a and PRDM16 in mice clearly inter-
feres with the function or/and development of BAT. Detailed
knowledge of these pathways may offer promising opportunities
to manipulate BAT in vivo for therapeutic regimens to counteract
obesity and type 2 diabetes.
It is now clear that two different types of brown adipocytes
exist, and these have distinct developmental origins. Classical
brown adipocytes residing in the interscapular and perirenal
regions develop from myoblastic-like Myf5-positive precursors
(Seale et al., 2008) that differentiate into brown adipocytes
through the action of transcriptional regulators PRDM16 and
C/EBPb (Kajimura et al., 2009; Seale et al., 2008). Furthermore,
global gene expression analyses indicate that classical inter-
scapular brown fat precursors have a gene profile overlapping
that of skeletal muscle cells (Timmons et al., 2007). On the other
hand, pockets of a second, distinct type of UCP1-positive adipo-
cytes are found sporadically in WAT of adult animals that have
been exposed to chronic cold or b-adrenergic agonists. These
inducible brown-like adipocytes (beige or brite cells) possess
many of the biochemical and morphological characteristics of
classical brown adipocytes, including the presence of multilocu-
lar lipid droplets (Frontini and Cinti, 2010). However, they arise
from a non-Myf5 cell lineage and, hence, have distinct origins
from the classical brown adipocytes. Indeed, it has been shown
previously that epidydimal WAT-derived brite cells that are
induced by rosiglitazone do not express myocyte-enriched
genes (Petrovic et al., 2010). In addition, adipogenic Sca-1+/
CD45/Mac1progenitors from different adipose depots
showed unique molecular signatures (Schulz et al., 2011).
Because the emergence of inducible-brown adipocytes in
WAT is associated with a protection against obesity and meta-
bolic diseases in rodent models (Cederberg et al., 2001; Leo-
nardsson et al., 2004; Seale et al., 2011), an important challenge
is to understand the molecular mechanisms by which environ-
mental cues stimulate the development of these beige/brite
cells. In this regard, it has been shown that activation of PPARg
by synthetic ligands induces a brown fat-like gene program in
WAT (Fukui et al., 2000; Petrovic et al., 2010; Rong et al.,
2007; Sell et al., 2004; Tai et al., 1996; Vernochet et al., 2009;Wil-
son-Fritch et al., 2004). Mechanistically, these drugs function by
directly binding to and activating PPARg and PPAR-response
elements (PPREs) on the promoter and/or enhancer of brownll Metabolism 15, 395–404, March 7, 2012 ª2012 Elsevier Inc. 395
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karma et al., 2007). However, this explanation concerning the
white to brown adipocyte transition cannot be considered
adequate or complete for the following reasons. First, PPARg
functions as a master regulator of both white and brown adipo-
cytes (reviewed in [Farmer, 2006]). PPARg is expressed abun-
dantly and equally in white fat and brown fat, and is required
for the development of both cell types (He et al., 2003; Imai
et al., 2004). Notably, overexpression of PPARg in white adipo-
cytes does not induce a white-to-brown fat conversion (Sugii
et al., 2009). Hence, it is not clear why activation of PPARg by
synthetic compounds should give such browning effects.
Second, treatment with PPARg ligands formultiple days appears
to be required for this effect (Petrovic et al., 2010). Such slow
kinetics is certainly not consistent with a direct action through
PPAR response elements, which would be expected to occur
within hours. Hence, it is essential to understand the structural
and molecular bases of the white-to-brown fat conversion
achieved through PPARg ligands in closer detail.
In this study, we find that PPARg ligands require full agonism
to induce a brown (beige/brite) fat gene program in subcuta-
neous (SC) WAT and that they do so through the activation of
the PRDM16 pathway. Surprisingly, such effects are due in large
measure to stabilization and accumulation of the PRDM16
protein, independent of PRDM16 mRNA levels. Thus, this may
provide a potential insight into designing and developing
synthetic compounds to increase energy expenditure by acti-
vating new brown adipocyte (beige/brite cell) development.
RESULTS
Full Agonism of PPARg Is Required to Activate
a Thermogenic Brown Fat Gene Program in
Subcutaneous White Fat
Antidiabetic PPARg ligand drugs, such as rosiglitazone, have
been shown to have the ability to turn on a thermogenic gene
program in brown fat and to activate a browning of white adipose
tissues (Fukui et al., 2000; Petrovic et al., 2010; Rong et al., 2007;
Sell et al., 2004; Tai et al., 1996; Vernochet et al., 2009; Wilson-
Fritch et al., 2004). Although these drugs are full agonists for
PPARg, recently they have been shown to have a second
activity, in addition to classical agonism: blocking the phosphor-
ylation of PPARg by cdk 5 at serine 273 (Choi et al., 2010). We
therefore asked whether the actions of PPARg ligands on brown
fat-selective gene expression were correlated with classical
receptor transcriptional agonism per se. To this end, we
compared the browning effect by a well-known agonist thiazoli-
dinedione (TZD) compound, rosiglitazone, with the effects of
several antidiabetic PPARg ligandswith weak or partial agonism.
These include non-TZD compounds, such as MRL24, nTZDpa,
Mbx-102, and BVT.13, which have been shown to have relatively
weak agonist properties (Berger et al., 2003; Gregoire et al.,
2009; Ostberg et al., 2004). As shown in Figure 1A, chronic treat-
ment of primary adipocytes derived from inguinal WAT with 1 mM
rosiglitazone robustly induced mRNA expression for several
brown fat-selective genes, including ucp1 (721-fold) and cidea
(128-fold). This effect was not due to an enhancement of adipo-
genesis per se, because the induction was still significant when
the mRNA levels for these genes were normalized to those of396 Cell Metabolism 15, 395–404, March 7, 2012 ª2012 Elsevier Inc.fabp4, an adipogenic marker gene (Figure S1A available online).
In contrast, the synthetic PPARg ligands with weak agonism, at
doses well above their respective KDs, had very modest or no
effects on the expression of these brown fat-selective genes.
Such effects were highly correlated with the transcriptional
activity of PPARg on PPREs, as assessed by a luciferase assay
(Bruning et al., 2007; Choi et al., 2010). Our results strongly
suggest that the effects of these compounds on ucp1 and other
brown-fat selective genes require strong classical agonism.
We next asked whether rosiglitazone had a preferential effect
on the brown-fat gene program in either the visceral or SC WAT
depot in vivo. As shown in Figures 1B and S1B, treatment with
rosiglitazone at 10 mg/kg for 10 days preferentially increased
brown fat-selective genes, such as ucp1, cidea, and cox8b, in
two different SC WAT depots (i.e., inguinal WAT and anterior
SC WAT). On the other hand, this effect was modest or minimal
in three distinct visceral WAT depots, including epidydimal,
retroperitoneal, and mesenteric WAT. Importantly, the preferen-
tial browning effects by rosiglitazone on SC WAT compared to
visceral WAT appear to be cell autonomous, in that it occurred
in cultured adipocytes. As shown in Figure 1C, treatment with ro-
siglitazone at 1 mM robustly increased the brown fat gene
expression of ucp1, cidea, and pgc1a in the primary adipocytes
differentiated from the stromal-vascular fraction (SVF) of inguinal
WAT. This induction was much smaller in the primary adipocytes
derived from the SVF of the epidydimal WAT depot. Interestingly,
mRNA for prdm16, a dominant regulator of classical brown fat
development, was highly enriched in the inguinal adipocytes
but was only modestly increased by the rosiglitazone treatment.
There was no significant difference in the expression of rb,
a known negative regulator of brown fat-cell fate (Hansen
et al., 2004) (Figure S1C).
PRDM16 Is Required for the Development of
Rosiglitazone-Inducible Brown Adipocyte
We next asked whether recently PRDM16 was required for rosi-
glitazone-induced activation of white-to-brown fat (beige/brite)
cell conversion. To do this, primary preadipocytes from inguinal
WAT were infected with adenoviral vectors expressing short-
hairpin RNA targeting PRDM16 (sh-PRDM16) or a scramble
control (sh-scr) in the presence or absence of rosiglitazone (Fig-
ure 2A). As shown in Figure 2B, rosiglitazone treatment slightly
enhanced adipogenesis; however, knockdown of PRDM16 did
not affect adipogenesis per se, as shown by Oil-Red-O staining
of accumulated lipid. Next, we systematically analyzed how rosi-
glitazone-induced gene expression in these cells was affected
by depletion of PRDM16 using Affimetrix microarray analyses.
As shown in Figures 2C and 2D, we identified 194 genes in total
that were significantly increased by rosiglitazone by 2-fold or
greater (p < 0.05). Importantly, expression of 147 of these genes
(75.8%) was significantly blunted or completely abolished by the
PRDM16 shRNA (PRDM16-dependent gene set, Table S1). No
significant change was observed in 47 genes (PRDM16-inde-
pendent gene set, 24.2%, shown in Table S2). The induction of
key brown fat/thermogenic genes, such as ucp1, cidea, pgc1a,
and cox8b, were all significantly reduced by the PRDM16 knock-
down. In contrast, expression of elovl3, fgf21, pgc1b, and car4
was not affected by depletion of PRDM16 (Figure 2D). Western
blot analysis showed that UCP1 protein levels were severely
Figure 1. Preferential Browning Effects in Subcutaneous WAT Requires Full Agonism of PPARg
(A) Primary inguinal white preadipocytes were differentiated in the presence of full or partial agonists for PPARg, such as rosiglitazone (rosi), MRL24, nTZDpa,
Mbx-102, and BVT.13. mRNA levels for brown fat-selective genes (ucp1 and cidea) were analyzed by qRT-PCR. *p < 0.05, **p < 0.01 relative to control.
(B) WT C57BL/6J mice were injected IP with saline or rosiglitazone at 10mg/kg for 10 days. mRNA levels for ucp1and cidea were measured by qRT-PCR in
interscapular BAT, inguinal WAT (Ing), anterior subcutaneous WAT (AntSC), epidydimal WAT (Epi), retroperitoneal WAT (retroP), and mesenteric WAT (Mesent).
*p < 0.05, **p < 0.01 relative to saline control.
(C) mRNA levels for ucp1, cidea, pgc1a, and prdm16 were measured by qRT-PCR in primary adipocytes differentiated from SVF derived from inguinal WAT and
from epidydimal WAT in the presence or absence of rosiglitazone. *p < 0.05, **p < 0.01 relative to control. x p < 0.01 relative to epidydimal cells treated with
rosiglitazone. Data are expressed as means ± SEM.
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ulated adipocytes (Figure 2E).
Next, to examine whether rosiglitazone alters the ability of
beige/brite cells to dissipate energy in a PRDM16-dependent
manner, oxygen consumption in control and PRDM16-depleted
cells was measured in the presence or absence of rosiglitazone.
As shown in Figure 2F, rosiglitazone significantly increased
uncoupled respiration at the basal state. Furthermore, the rosi-
glitazone-treated cells had greater total and uncoupled respira-
tion in response to cAMP stimulation. In contrast, no significantCechangewas observed in the PRDM16-depleted cells in response
to rosiglitazone and/or cAMP. These results clearly indicate that
PRDM16 is required for the rosiglitazone-induced brown fat
gene program and thermogenic function of SC WAT.
PRDM16 and Rosiglitazone Synergistically Promote the
Development of Inducible-Brown Adipocyte
Because visceral fat expresses less PRDM16mRNA than the SC
fat, we next asked whether enhanced PRDM16 expression
would be sufficient to sensitize the visceral white adipocytes toll Metabolism 15, 395–404, March 7, 2012 ª2012 Elsevier Inc. 397
Figure 2. PRDM16 Is Required for the Browning of White Adipocytes in Response to Rosiglitazone
(A) mRNA levels for Prdm16 were measured by qRT-PCR in primary inguinal adipocytes infected with a control scramble shRNA (sh-scr) or shRNA targeting
PRDM16 (sh-PRDM16). **p < 0.01 relative to sh-scr.
(B) Oil red O staining of primary inguinal cells at day 7 of differentiation in the presence or absence of rosiglitazone.
(C) Microarray analysis of the differentiated inguinal adipocytes expressing sh-scr or sh-PRDM16 in the presence or absence of rosiglitazone.
(D) mRNA levels for the indicated genes were analyzed by qRT-PCR. *p < 0.05, **p < 0.01 relative to control cells. x p < 0.01 relative to the cells expressing
sh-PRDM16 treated with rosiglitazone.
(E) UCP1 protein levels were analyzed by western blotting. The cells were treated with or without forskolin (cAMP), at 10 mM for 6 hr.
(F) Total and uncoupled cellular respiration were measured in primary inguinal adipocytes expressing sh-scr or sh-PRDM16 in the presence or absence of
rosiglitazone and/or. dibutyryl cAMP. **p < 0.01. Data are expressed as means ± SEM.
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Figure 3. PRDM16 and Rosiglitazone Synergistically Promote the Browning of White Adipocytes
(A) PRDM16 protein levels were analyzed by western blotting in epidydimal WAT, inguinal WAT, and interscapular BAT from WT and PRDM16 transgenic mice.
Pol-II was blotted as a loading control.
(B) mRNA levels for ucp1, cidea, pgc1a, and cox8b were measured by qRT-PCR in primary epidydimal adipocytes from WT and PRDM16 transgenic mice.
**p < 0.01 relative to control. x p < 0.01 relative to WT cells treated with rosiglitazone.
(C) mRNA levels for elovl3 and fabp4 were measured by qRT-PCR.
(D) WT and PRDM16 transgenic mice were injected IP with saline or rosiglitazone at 10mg/kg for 10 days. The inguinal WAT depots were fixed and stained by
H&E. Scale bar, 100 mm.
(E) Immunohistochemistry for UCP1 expression from samples in (D). Scale bar, 100 mm.
(F) mRNA levels for ucp1 and prdm16 were quantified by qRT-PCR from samples in (D). *p < 0.05, **p < 0.01. Data are expressed as means ± SEM.
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To test this idea, we used fabp4-PRDM16 transgenic mice in
which transgenic expression of prdm16 was driven by the 5
kb fabp4 (aP2) promoter/enhancer (Seale et al., 2007). Impor-
tantly, PRDM16 protein levels in the epididymal WAT of
PRDM16 transgenic mice were nearly equivalent to the endoge-
nous PRDM16 levels observed in the inguinal WAT of wild-type
(WT) mice (Figure 3A). Primary visceral preadipocytes were iso-
lated from epidydimal WAT ofWT and PRDM16 transgenic mice,Ceand were differentiated into mature adipocytes in the presence
or absence of rosiglitazone at 1 mM. As shown in Figure 3B,
rosiglitazone-mediated induction of brown fat-selective genes,
including ucp1, cidea, pgc1a, and cox8b, were all robustly
enhanced in visceral adipocytes derived from SVF cultures of
the PRDM16 transgenic mice compared to the controls. On
the other hand, mRNA expression of elovl3 and an adipogenic
marker fabp4 were not affected by transgenic expression of
PRDM16 (Figure 3C).ll Metabolism 15, 395–404, March 7, 2012 ª2012 Elsevier Inc. 399
Figure 4. Browning of the White Adipocytes Is Tightly Linked to the Rosiglitazone-Induced PRDM16 Protein Stabilization
(A) Primary inguinal cells from SVF were differentiated in the presence or absence of rosiglitazone at 1 mM for 4 days (day4R) and 8 days (day8R), and for 4 days
with rosiglitazone and an additional 4 days without rosiglitazone (day4R-D4off). PRDM16 protein levels were analyzed by western blotting. Pol-II was blotted as
a loading control.
(B) Primary inguinal WAT-derived adipocytes were treated with full or partial agonists for PPARg. PRDM16 protein levels were analyzed by western blotting.
b-actin was blotted as a loading control.
(C) PRDM16 protein levels were analyzed by western blotting in primary adipocytes treated with rosiglitazone at different doses.
(D) PRDM16 protein levels were analyzed by western blotting in BAT and inguinal WAT isolated fromWTmice. Mice were injected IP with saline or rosiglitazone at
10 mg/kg for 10 days.
(E) PRDM16 protein levels in a cycloheximide chase experiment were analyzed by western blotting. Top, control cells. Bottom, rosiglitazone-treated cells.
(F) Regression analysis of PRDM16 protein stability in (E).
(G) F442A cells expressing flag-tagged PRDM16 were differentiated in the presence or absence of rosiglitazone. Cells were treated with a proteasome inhibitor
MG132 (10 mM) for 16 hr prior to harvesting the cells. PRDM16was immunoprecipitated using flag antibody, and ubiquitin was detected bywestern blotting. Total
PRDM16 protein is shown in the bottom panel.
Cell Metabolism
PRDM16 Controls Browning of White Fat
400 Cell Metabolism 15, 395–404, March 7, 2012 ª2012 Elsevier Inc.
Cell Metabolism
PRDM16 Controls Browning of White FatTo further test whether PRDM16 synergistically enhanced the
rosiglitazone-induced browning action in vivo, WT and PRDM16
transgenic mice were treated with saline or rosiglitazone at
10 mg/kg for 10 days. As shown in Figure 3D, multilocular adipo-
cytes, a morphological characteristic of brown adipocytes, were
sporadically observed in the WT mice treated with rosiglitazone
or in the PRDM16 transgenic mice treated with saline. When
PRDM16 transgenic mice were treated with rosiglitazone, the
emergence of multilocular adipocytes was dramatically induced
(Figure 3D, bottom right). These multilocular cells were indeed
UCP1-positive adipocytes, as shown by immunohistochemistry
(Figure 3E). Gene expression analyses also illustrated that trans-
genic expression of PRDM16, together with rosiglitazone, syner-
gistically induced ucp1 gene expression in vivo (Figure 3F).
These data clearly indicate that PRDM16 synergistically acti-
vates the inducible brown fat (beige/brite) gene program
together with the PPARg agonist.
Rosiglitazone Stimulates a Powerful Stabilization of the
PRDM16 Protein
A key issue is the molecular mechanism by which the PPARg
agonist activates a brown fat phenotype in a PRDM16-depen-
dent manner. We have previously shown that PRDM16 directly
interacted with PPARg and coactivated the transcriptional
activity of PPARg (Seale et al., 2008). However, this PRDM16-
PPARg interaction was not enhanced by rosiglitazone (Fig-
ure S2A), suggesting that alternative mechanisms were
operative.
We examined PRDM16 protein levels during the rosiglitazone-
induced white-to-brown fat conversion in inguinal adipocytes.
As shown in Figure S2B, no significant increase was found in
endogenous PRDM16 mRNA expression in cells with a 4- day
treatment. Minor but statistically significant increases were
observed in PRDM16 mRNA with an 8-day treatment and with
a 4-day treatment followed by a 4-day removal. However,
a very striking increase in PRDM16 protein level was observed
with rosiglitazone treatment at days 4 and 8; this correlated
very well with the induction of the brown/beige fat genes, such
as ucp1 and pgc1a (Figures 4A and S2C). Similarly, a time
course experiment showed that induction of this beige/brite fat
gene program required at least a 3-day treatment with rosiglita-
zone. This correlated well with the PRDM16 protein accumula-
tion but not with the induction of a well-known PPARg target
gene, fabp4 (Figures S2D and S2E).
To further investigate how PPARg ligands regulate PRDM16
protein levels, we analyzed PRDM16 protein levels in primary
white adipocytes treated with a variety of full and partial PPARg
ligands including SR1664, which was shown previously to block
the Cdk5-mediated phosphorylation of PPARg at S273 with no
agonism (Choi et al., 2011). As shown in Figure 4B, PRDM16
protein levels were robustly induced by two strong PPARg(H) Correlation analysis between PRDM16 protein levels and ubiquitinated PRDM
(I) PRDM16 protein levels were analyzed by western blotting in primary inguinal ad
low- or high-tires adenovirus.
(J) mRNA levels for prdm16 and ucp1 were measured by qRT-PCR in (I). **p < 0.0
cells without rosiglitazone treatment.
(K) Correlation analyses between ucp1mRNA levels and PRDM16 protein levels (
expressed as means ± SEM.
Ceagonists, rosiglitazone and pioglitazone. On the other hand,
other weaker agonists had modest or no effects on the
PRDM16 protein. No induction was observed following treat-
ment with SR1664. The induction of the PRDM16 protein was
highly correlated with the browning effects, as judged by the
induction of ucp1 mRNA expression (Figure S3A). In addition,
a dose-response experiment showed that rosiglitazone at doses
of 50 nM and higher significantly increased PRDM16 protein
levels (Figure 4C), consistent with the previous report that rosigli-
tazone binds to the ligand-binding domain of PPARgwith a KD of
43nM (Lehmann et al., 1995). These effects also correlated well
with the induction of ucp1 mRNA levels (Figure S3B). Further-
more, the rosiglitazone-mediated induction of the PRDM16
protein was largely blocked by PPARg antagonists (Figure S3C).
Importantly, PRDM16 protein was highly increased by rosiglita-
zone in vivo, both in BAT and inguinal WAT from WT (Figure 4D)
and PRDM16 transgenic mice (Figure S3D), whereas there was
modest or no effect on PRDM16 mRNA levels (Figure S3E).
We next asked whether this increased protein accumulation
for PRDM16 was due to changes in the rate of protein degrada-
tion or altered mRNA translation. To this end, the stability of
PRDM16 protein was investigated with a cycloheximide chase
experiment. The data in Figures 4E and 4F clearly showed that
rosiglitazone treatment of cells treated with cycloheximide
dramatically extended the half-life of PRDM16, from 5.9–17.5 hr.
To further investigate the extent to which PPARg ligands regu-
late the stability of PRDM16 protein stability, we examined
whether PRDM16was ubiquitinated in response to rosiglitazone.
PRDM16 ubiquitination was detected by immunoprecipitation of
PRDM16 followed by immunoblotting with an antibody against
ubiquitin. As shown in Figure 4G, ubiquitination of PRDM16
was strikingly reduced by rosiglitazone in the presence or
absence of proteasome inhibitor MG132. Importantly, there
was a statically significant inverse correlation between the
changes in the PRDM16 protein levels and the changes in the
ubiquitinated PRDM16 protein levels in response to rosiglitazone
(r =0.499, p = 0.0243, Student’s t test, Figure 4H). Furthermore,
addition of MG132 largely blocked the protein degradation of
PRDM16 after the removal of rosiglitazone (Figure S3F). These
results strongly indicate that prolongation of the half-life of
PRDM16 protein by PPARg ligands is regulated, in part, through
the ubiquitin-proteasome pathway.
Finally, we investigated whether the browning effect of rosigli-
tazone could be more closely associated with these effects on
levels of the PRDM16 mRNA or protein. As shown in Figures 4I
and 4J, PRDM16 mRNA levels were modestly but significantly
reduced by low titers of the adenoviral vectors expressing the
PRDM16 shRNA, but its protein level reached a level almost
equivalent to that in control cells treated with rosiglitazone. On
the other hand, high titers of the adenovirus of PRDM16 shRNA
reduced PRDM16 mRNA and also completely abolished the16 levels.
ipocytes infected with control scramble shRNA or shRNA targeting PRDM16 at
1 relative to sh-scr control cells treated with rosiglitazone. x p < 0.01 relative to
left), and between ucp1mRNA levels and prdm16mRNA levels (right). Data are
ll Metabolism 15, 395–404, March 7, 2012 ª2012 Elsevier Inc. 401
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PRDM16 Controls Browning of White FatPRDM16 protein accumulation. As judged by ucp1 mRNA
expressions, induction of brown fat gene program by rosiglita-
zone correlated much more tightly with the PRDM16 protein
levels than with PRDM16 mRNA levels. Indeed, there was
a powerful positive correlation (r2 = 0.784, p < 0.0001) between
the changes of ucp1 mRNA levels and the changes of
PRDM16 protein levels caused by rosiglitazone treatment (Fig-
ure 4K, left). Despite a significant correlation between the
changes of ucp1 mRNA levels and the changes of prdm16
mRNA levels (r2 = 0.528, p < 0.001), the correlation between
ucp1 mRNA levels and PRDM16 protein levels was significantly
tighter than that of ucp1 mRNA levels and prdm16 mRNA levels
(Figure 4K, right). Population correlation coefficient of these two
was significantly different (p < 0.001, Z-test). Taken together,
these results strongly suggest that rosiglitazone-induced
white-to-brown fat conversion is regulated in large measure
through enhanced stability of PRDM16 protein.
DISCUSSION
PRDM16 is a 140kDa zinc-finger protein that was originally iden-
tified at a chromosomal breakpoint of t(1;3)(p36;q21)-positive
human acute myeloid leukemia cells (Mochizuki et al., 2000).
We have previously shown that PRDM16 acts as a molecular
switch to induce brown fat development in a subset of Myf5-
positive, myoblast-like precursor cells during embryological
development. It does this through interactions with several tran-
scription factors, such as C/EBPb, PPARg, PGC-1a/b, and
C-terminal binding proteins (Kajimura et al., 2008, 2009; Seale
et al., 2007, 2008). The present studies show that PRDM16 plays
a pivotal role in the development of beige/brite cells in SC WAT
induced by PPARg agonists (Figure S4). A key and unexpected
mechanism here is that this drug causes a greatly enhanced
accumulation of PRDM16 due to prolongation of the half-life of
this protein.
The browning effect on adipose tissues by PPARg agonists
was first suggested to be mediated by the direct activation of
the thermogenic genes via PPREs in their promoter/enhancer
(Sears et al., 1996; Tai et al., 1996; Viswakarma et al., 2007).
Although this model still may have some validity, the slow induc-
tion of the expression of ucp1 and other thermogenic genes by
rosiglitazone (at least 3 days or longer) suggests a less direct
mechanism. Most direct gene regulatory effects by nuclear
receptors and their agonists occur within several hours after
ligand treatment (e.g., induction of fabp4 mRNA expression by
rosiglitazone in Figure S2E). On the other hand, the stabilization
of the PRDM16 protein by rosiglitazone shown here can explain
several aspects of this phenomenon quite well. First, substan-
tially greater expression of PRDM16 mRNA in the SC fat,
compared to the visceral depots, allows a protein stabilization
mechanism to produce biologically active amounts of this factor
only in the SC fat. Second, rosiglitazone treatment robustly
extends the half-life of PRDM16 protein from 5.9–17.5 hr.
Thus, accumulation of the PRDM16 protein to biologically active
levels, as shown in Figures 4E and 4F, would be expected to take
several half-lives, consistent with the slow pace of cellular
browning by rosiglitazone. Furthermore, an inverse correlation
between the PRDM16 protein levels and the ubiquitinated
PRDM16 levels clearly indicates that PPARg ligand-mediated402 Cell Metabolism 15, 395–404, March 7, 2012 ª2012 Elsevier Inc.RDM16 protein stabilization is regulated, at least in part, through
the ubiquitin-proteasome pathway. Future studies will aim at
identifying factors that directly control PRDM16 ubiquitination
and its protein stability.
The structural basis of PPARg activation by agonists has been
extensively studied. Full PPARg agonists, such as rosiglitazone,
bind to and stabilize helix12 of its ligand-binding domain (LBD).
This allows interaction with known coactivators such as SRC1
(Nolte et al., 1998). On the other hand, partial agonists such as
MRL24 and nTZDpa, preferentially affect helix3 and the b-sheet
region, with minimum influence on helix12 (Bruning et al., 2007).
The results shown here, which indicate that these partial
agonists had little or no browning effects, implies that structural
changes in helix3 and the b-sheet region of the LBD may not be
sufficient to induce a white-to-brown fat conversion. Of note,
Farmer and colleagues have recently shown that mutations
within helix 7 of the PPARg LBD (E365 and F372) blunted the
troglitazone-mediated browning of Swiss 3T3-adipocytes (Ver-
nochet et al., 2009). Thesemutations also caused impaired regu-
lation of a subset of PPARg target genes (Vernochet et al., 2009,
2010; Wang et al., 2008). In addition, a dominant-negative muta-
tion (P465L) near the activating function-2 (AF-2) domain of
helix12, originally discovered in human lipodystrophy patients
with extreme insulin resistance, causes an impairment in
cAMP-induced recruitment of brown adipocytes in WAT in vivo
(Gray et al., 2006). The emerging question is how structural
changes in the helix7 or the helix 12 of PPARg affect browning
activity and whether these changes also affect PRDM16 protein
stability. If it is possible to develop PPARg ligands that affect
PRDM16 protein accumulation without full agonist activity,
such compounds could have plausible therapeutic activity
toward obesity and diabetes.
EXPERIMENTAL PROCEDURES
Cell Culture
Adipocyte differentiation was induced by treating confluent cells in DMEM/F12
medium (D-glucose, 17.51 mM) containing 10% FBS, 0.5 mM isobutylmethyl-
xanthine, 125 nM indomethacin, 1 mM dexamethasone, 850 nM insulin, and
1 nM T3. Two days after induction, cells were switched to the maintenance
medium containing 10% FBS, 850 nM insulin, and 1 nM T3.
Animals
Animal experiments were performed according to procedures approved by
Institutional AnimalCare andUseCommittee at Beth Israel DeaconessMedical
Center and at UCSF. Male C57BL/6J mice between 6 and 8 weeks old were
intraperitoneally injected daily with 10 mg/kg rosiglitazone for 10 days. For
histological analyses, paraffin-embedded sections were incubated with anti-
UCP1 antibody (Chemicon), as described previously (Kajimura et al., 2009).
Gene Expression Analysis
Quantitative real-time PCR (qRT-PCR) was performed with SYBR green fluo-
rescent dye using an ABI9300 PCR machine or ABI ViiA7. TATA-binding
protein (TBP) served as an internal control. Primer sequences are provided
in Table S3. For a microarray analysis, Affymetrix GeneChip Mouse Genome
430 2.0 array was used according to established methods (Lockhart et al.,
1996). The array datawere analyzed using the DNA-Chip Analyzer (dChip) soft-
ware (Li and Wong, 2001). The statistical significance of differences in gene
expression was assessed by unpaired Student’s t test (p < 0.05).
Protein Stability Assay and Western Blotting
Primary cells were incubated in medium containing 20 mg/ml cycloheximide in
the presence or absence of rosiglitazone. Total cell lysates or nuclear extracts
Cell Metabolism
PRDM16 Controls Browning of White Fatwere isolated and separated by SDS-page. Antibodies for PRDM16 (Seale
et al., 2011), ubiquitin (Santa Cruz), UCP1 (Abcam), b-actin, M2 flag (Sigma),
or Pol-II (Cell Signaling) were used for western blotting.
Oxygen Consumption Assay
Cellular oxygen consumption was measured as described previously (Kaji-
mura et al., 2009). For cAMP-induced respiration assays, fully differentiated
adipocytes were incubated with 0.5 mM dibutyryl cyclic AMP for 12 hr prior
to measuring oxygen consumption.
Statistical Analyses
Significant differences between two groups were assessed by two-tailed
Student’s t test with unequal variance. Data are expressed as means ± SEM.
ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number for the microarray
data reported in this paper is GSE35011.
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